COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST FOR TREATING PATIENTS WITH NON-MICROSATELLITE INSTABILITY-HIGH OR PROFICIENT MISMATCH REPAIR COLORECTAL CANCER

COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST FOR TREATING PATIENTS WITH NON-MICROSATELLITE INSTABILITY-HIGH OR PROFICIENT MISMATCH REPAIR COLORECTAL CANCER

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mism...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Chartash, Elliot K, McClanahan, Terrill K, Healy, Jane Anne
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.